A Study on Efficacy and Safety of Menopur® Multidose in Korean Female Patients With Infertility

Non-Interventional Clinical Study on Efficacy and Safety of Highly Purified Human Menopausal Gonadotrophin (HP-hMG) Menopur® Multidose in Korean Female Patients With Infertility

The purpose of this study is to investigate the ongoing pregnancy rates at 10-11 weeks after embryo transfer in patients treated with Menopur® Multidose

Inclusion Criteria:

• Decision made to prescribe Menopur® multidose according to Summary of product characteristics

• The study cycle will be either

  • 1st controlled ovarian stimulation cycle ever, or
  • 2nd controlled ovarian stimulation cycle ever, or
  • 1st or 2nd controlled ovarian stimulation cycle after having achieved ongoing pregnancy in a previous controlled ovarian stimulation cycle (note: the subject cannot be included if she has had made more than one failed cycle before the cycle resulting in ongoing pregnancy)

Exclusion Criteria:

• Known ovarian disease (e.g. ovarian cysts, polycystic ovarian disease etc.)

• Diagnosed as "poor responder", defined as either

  • >20 days of gonadotrophin stimulation in a previous controlled ovarian stimulation cycle, or
  • any previous cancellation of a controlled ovarian stimulation cycle due to limited follicular response, or
  • development of less than 4 follicles ≥15 mm in a previous controlled ovarian stimulation cycle

• Ovarian hyperstimulation syndrome (OHSS)